Therapeutics News and Research

RSS

Highly caffeinated alcoholic drinks may induce changes in the adolescent brain similar to cocaine

Drinking highly caffeinated alcoholic beverages triggers changes in the adolescent brain similar to taking cocaine, and the consequences last into adulthood as an altered ability to deal with rewarding substances, according to a Purdue University study.

25 Oct 2016

Novel approach could help counter Influenza A virus in immune-compromised patients

To infect its victims, influenza A heads for the lungs, where it latches onto sialic acid on the surface of cells.

24 Oct 2016

Combination of two drugs could be effective strategy to target T-cell lymphocytic leukemia

Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.

24 Oct 2016

Fission yeast could help discover novel cancer drugs

Cancer is a notoriously difficult disease to treat. Not only do a wide variety of cancers exist, requiring specialized treatments for each type, but cancer cells within an individual can morph and render previously potent therapeutics ineffective.

24 Oct 2016

International scientists create first 3D atomic-level image of human cannabinoid receptor 1

In a discovery that advances the understanding of how marijuana works in the human body, an international group of scientists, including those from the Florida campus of The Scripps Research Institute (TSRI), have for the first time created a three-dimensional atomic-level image of the molecular structure activated by tetrahydrocannabinol (THC), the active chemical in marijuana.

24 Oct 2016

Scientists discover new option for treating malignant pleural mesothelioma

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malignant pleural mesothelioma.

24 Oct 2016

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered a mechanism that confers resistance to drugs used to treat certain types of acute myeloid leukemia (AML).

24 Oct 2016

UA neuroscientists receive $10.3 million grant to find cause for heightened risk of Alzheimer's in women

Why do more women than men get Alzheimer's disease? In their quest to find the answer, neuroscientist Roberta Diaz Brinton, PhD, and her collegues in the Center for Innovation in Brain Science at the University of Arizona Health Sciences, have been awarded a $10.3 million five-year Program Project Grant from the National Institute on Aging at the National Institutes of Health.

21 Oct 2016

Study shows how damage to RNA-binding protein contributes to ALS

Although only 10 percent of amyotrophic lateral sclerosis (ALS) cases are hereditary, a significant number of them are caused by mutations that affect proteins that bind RNA, a type of genetic material.

21 Oct 2016

Esperite's business unit develops therapy for Crohn's disease perianal fistulas

Esperite's business unit The Cell Factory in collaboration with Women's and Children's Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).

21 Oct 2016

Study sheds new insights on immune cells involved in fighting dengue virus infection

India suffers from the highest number of dengue infections in the world, but there are few studies, if any, to understand the immune cells involved in fighting the virus.

21 Oct 2016

Targeting TASINs can be viable approach for preventing colon cancer, research reveals

A small molecule called TASIN-1 can selectively kill cells with a mutation that is considered to be a precursor to colon cancer, while sparing related normal cells, UT Southwestern Medical Center cancer biologists have demonstrated.

20 Oct 2016

New study raises serious safety concerns in clinical use of caspase inhibitors for liver injury

Many acute and chronic liver diseases, including alcoholic hepatitis, result from apoptotic (programmed) cell death mediated by the enzyme caspase.

20 Oct 2016

Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics

Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson’s disease.

19 Oct 2016

Salk scientist wins NIH grant for new technique to precisely target specific cells using sound waves

Salk Associate Professor Sreekanth Chalasani has been awarded a grant from the National Institutes of Health's Brain Research through Advancing Innovative Neurotechnologies Initiative for developing a way to selectively activate brain, heart, muscle and other cells using ultrasonic waves, which could be a boon to neuroscience research as well as medicine.

14 Oct 2016

Researchers to evaluate new treatment strategy for treating infants with perinatal brain injury

Perinatal brain injury often results in severe developmental disabilities, including neurodevelopmental delay and cerebral palsy.

13 Oct 2016

High folate intake may increase risk of peripheral neuropathy in older adults with common gene variant

Consuming too much folate (vitamin B9) is associated with increased risk for a nerve-damage disorder in older adults who have a common genetic variant.

12 Oct 2016

New image analysis technique helps better identify and distinguish between two cancer cell types

Brown University researchers have developed a new image analysis technique to distinguish two key cancer cell types associated with tumor progression.

12 Oct 2016

Researchers describe novel host-oriented therapeutic approach for preventing lethal immune responses

Staphylococcal and streptococcal infections affect millions of individuals each year. They are a leading cause of sepsis and account for many cases of pneumonia and post-surgical infections.

8 Oct 2016

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

Therapeutics News and Research

Highly caffeinated alcoholic drinks may induce changes in the adolescent brain similar to cocaine

Novel approach could help counter Influenza A virus in immune-compromised patients

Combination of two drugs could be effective strategy to target T-cell lymphocytic leukemia

Fission yeast could help discover novel cancer drugs

International scientists create first 3D atomic-level image of human cannabinoid receptor 1

Scientists discover new option for treating malignant pleural mesothelioma

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

UA neuroscientists receive $10.3 million grant to find cause for heightened risk of Alzheimer's in women

Study shows how damage to RNA-binding protein contributes to ALS

Esperite's business unit develops therapy for Crohn's disease perianal fistulas

Study sheds new insights on immune cells involved in fighting dengue virus infection

Targeting TASINs can be viable approach for preventing colon cancer, research reveals

New study raises serious safety concerns in clinical use of caspase inhibitors for liver injury

Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics

Salk scientist wins NIH grant for new technique to precisely target specific cells using sound waves

Researchers to evaluate new treatment strategy for treating infants with perinatal brain injury

High folate intake may increase risk of peripheral neuropathy in older adults with common gene variant

New image analysis technique helps better identify and distinguish between two cancer cell types

Researchers describe novel host-oriented therapeutic approach for preventing lethal immune responses

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News